Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Commissioning Board

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

Artificial intelligence firm licenses Janssen candidates for development

UK-based BenevolentAI aims to move them into late-stage trials by mid-2017

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

- PMLiVE

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

- PMLiVE

NICE backs Eisai’s Halaven for breast cancer

Reverses 2012 rejection due to new data and patient access discount

- PMLiVE

NICE set to reject Merck’s Erbitux for head and neck cancer

Draft guidance rules the treatment does not provide value for money

- PMLiVE

‘Hard’ Brexit could mean a longer wait for new drugs, says report

Warns of deprioritised status if negotiators fail to secure access to the single market

Communicating with payers to improve patient access

A transforming NHS brings with it many opportunities. Working with payers to put patients at the heart of everything while reducing costs is fundamental to success.

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

- PMLiVE

Halesway changes name to FCB Halesway

Move aligns agency more closely with its parent company FCB Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links